You are not imagining it.
And you are not alone in it.
Perimenopause affects more than a billion women, lasts years, and has no single test that confirms it. HerMidlife explains what is actually happening in your body — clearly, accurately, and without minimising any of it.
Free to read. No sign-up required. Clinical claims on this site are attributed to a named guideline or peer-reviewed source.
The global picture
Midlife is not a niche.
women postmenopausal by 2025
World Health Organization
women reach menopause each year
Global demographic estimates
experience vasomotor symptoms
SWAN cohort · Menopause Society
of symptomatic women receive treatment
International survey data
A billion women, years of symptoms each, and a treatment gap that has never been closed. That gap is what this platform exists to address.
Why this keeps happening
The problem is rarely the woman.
It is usually the test.
During perimenopause, oestrogen does not decline in a smooth line. It fluctuates — sometimes reaching levels higher than in your twenties, sometimes dropping sharply within the same cycle. Follicle-stimulating hormone swings alongside it.
A blood test captures one moment inside that volatility. This is precisely why NICE guideline NG23 advises diagnosing perimenopause and menopause on symptoms alone in women over 45, without FSH testing. A “normal” result does not mean nothing is happening. It means the test was the wrong instrument for the question.
Combine that with consultations of ten to fifteen minutes and limited menopause teaching in most medical curricula, and the pattern women describe worldwide stops being surprising.
What this means practically: if you are over 45 with characteristic symptoms and cycle changes, you are entitled to a clinical conversation about treatment — regardless of what a hormone panel showed.
What women are told
— and what the evidence actually says
“Your bloods are normal.”
Hormone levels fluctuate too widely during perimenopause for a single sample to be diagnostic. NICE guidance advises against relying on FSH to diagnose menopause in women over 45.
“You’re too young for this.”
Perimenopause commonly begins in the early 40s and sometimes the late 30s. Premature ovarian insufficiency affects roughly 1 in 100 women before the age of 40.
“It’s anxiety — try an antidepressant.”
Risk of depressive symptoms approximately doubles during the transition, and the hormonal contribution is well documented. Antidepressants may genuinely help, but the hormonal driver should be assessed rather than skipped.
“HRT causes breast cancer.”
The 2002 WHI findings have been substantially reinterpreted since publication. For most healthy women under 60, or within ten years of menopause onset, benefits generally outweigh risks when symptoms are bothersome.
“Just wait — it will pass.”
Vasomotor symptoms last a median of roughly seven years. Genitourinary symptoms and accelerated bone loss do not resolve on their own and warrant active management.
What HerMidlife does
A reference you can trust,
and actually use.
Three things, done properly, rather than a dozen done thinly.
Understand what is happening
Perimenopause has more than forty recognised symptoms and no single diagnostic test. We explain the physiology in plain language — what fluctuating oestrogen actually does to your brain, bones, heart, sleep and mood — so the picture finally makes sense.
Read the guideRecognise it in yourself
A symptom library with prevalence data, the physiological mechanism behind each symptom, what genuinely helps, and the red flags that need investigating rather than reassurance. Written to be useful in a consulting room, not just reassuring on a phone.
Browse the symptom libraryGet taken seriously
Most women who are dismissed are dismissed because the consultation was too short and too vague. We give you the staging framework, the specific language, and the questions that turn a ten-minute appointment into a real clinical conversation.
Prepare for your appointmentThe transition, staged
Perimenopause is not one event.
It has stages.
Clinicians stage the transition using the STRAW +10 framework. Knowing roughly where you sit changes which symptoms are expected, which investigations are worthwhile, and which treatments are appropriate.
Late reproductive
Often late 30s – early 40s
Cycles are still regular but subtly shorter. Early-follicular FSH begins to rise. Many women first notice sleep and mood changes here — and are told nothing is wrong.
Early perimenopause
Variable onset
Persistent cycle-length variability of seven days or more. Oestrogen swings widely rather than falling steadily — which is why symptoms come and go, and why a single blood test is so often unhelpful.
Late perimenopause
Typically 1–3 years
Intervals of sixty days or more between periods. Vasomotor symptoms usually peak in this window and in the two years following the final period.
Postmenopause
From 12 months after the final period
Hot flushes gradually settle for most women. Genitourinary changes and bone loss do not — both are progressive without treatment, which is why long-term care matters more than short-term relief.
Framework: Stages of Reproductive Aging Workshop (STRAW +10), Harlow et al., 2012 — the international standard for staging reproductive ageing.
For clinicians
Built to be useful
inside the consultation.
Much patient-facing menopause content is either too vague to act on or quietly wrong. Ours is written so a GP can hand it over without hesitation — and so a patient arrives having already done the useful part of the history.
Symptom entries carry prevalence figures, the physiological mechanism, and explicit red flags requiring investigation.
Guidance is aligned to NICE NG23 and Menopause Society position statements, with sources named on the page.
Patients are directed toward staging and structured history-taking — never toward self-diagnosis or self-prescribing.
Route and formulation nuances (transdermal versus oral, micronised progesterone, low-dose vaginal oestrogen) are represented accurately.
The evidence we work from
NICE NG23
Menopause: identification and management. Diagnosis on symptoms alone over age 45; FSH not recommended for diagnosis in that group.
The Menopause Society — 2022 position statement
For healthy women under 60, or within ten years of menopause onset, hormone therapy benefits generally outweigh risks for bothersome vasomotor symptoms and prevention of bone loss.
SWAN longitudinal cohort
Median total vasomotor symptom duration of approximately 7.4 years, exceeding ten years where onset occurs in early perimenopause.
STRAW +10 — Harlow et al., 2012
International staging framework for reproductive ageing, used throughout this site.
World Health Organization
Population scale, cardiovascular and skeletal consequences, and the global treatment gap.
You should not have to become an expert to be believed.
But until that changes,
here is the knowledge.
Free, sourced, and written for the woman living it — and for the clinician she is about to see.